GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » EBITDA Margin %

JW (Cayman) Therapeutics Co (HKSE:02126) EBITDA Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. JW (Cayman) Therapeutics Co's EBITDA for the six months ended in Dec. 2023 was HK$0.0 Mil. JW (Cayman) Therapeutics Co's Revenue for the six months ended in Dec. 2023 was HK$0.0 Mil. Therefore, JW (Cayman) Therapeutics Co's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.

JW (Cayman) Therapeutics Co EBITDA Margin % Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co EBITDA Margin % Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial - - -2,115.17 -516.31 -377.18

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -1,342.42 -637.07 -510.54 -419.98 -

Competitive Comparison of JW (Cayman) Therapeutics Co's EBITDA Margin %

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's EBITDA Margin % falls into.


JW (Cayman) Therapeutics Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

JW (Cayman) Therapeutics Co's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-717.242/190.16
=-377.18 %

JW (Cayman) Therapeutics Co's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co  (HKSE:02126) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

JW (Cayman) Therapeutics Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » EBITDA Margin %
Comparable Companies
HKSE:02197 HKSE:02185 HKSE:06996 HKSE:06998 HKSE:03681 HKSE:01228 HKSE:02142 HKSE:09939 HKSE:01875 HKSE:00690 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
JWCTF:USA
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
Website
https://www.jwtherapeutics.com
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Executives
Li Dan 2202 Interest of your spouse
Li Yiping James 2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd. 2501 Other
Bristol-myers Squibb Company 2201 Interest of corporation controlled by you
Celgene Corporation 2201 Interest of corporation controlled by you
Juno Therapeutics, Inc. 2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd. 2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines